Roberts Brandi 4

What Happened

• Brandi Roberts, Chief Financial Officer of Definium Therapeutics (DFTX), was granted 150,000 restricted stock units (RSUs) on February 3, 2026. The grant is recorded at $0.00 per share (no cash paid). RSUs are a contingent right to receive shares if vesting conditions are met.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely within the usual two-business-day window).
• Transaction type/code: Award/Grant (A) — 150,000 RSUs acquired at $0.00.
• Grant terms: RSUs vest in 16 equal quarterly installments beginning June 1, 2026, subject to continuous service on each vesting date (per footnote).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• No sale, open-market purchase, or option exercise occurred as part of this filing.

Context

• RSUs are a form of equity compensation that convert to actual shares only when they vest; they do not represent immediately tradable shares. Because this is a granted award (not a market purchase or sale), it signals a compensation action rather than direct insider buying or selling for investment purposes.